Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.10 USD

94.10
1,891,045

-0.36 (-0.38%)

Updated Jul 12, 2024 03:59 PM ET

After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

by Zacks Equity Research

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone

by Zacks Equity Research

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

Maharathi Basu headshot

5 Stocks Favored by Brokers Amid Current Uncertainty

by Maharathi Basu

We believe that stocks like General Motors (GM), Cardinal Health (CAH), Deutsche Bank (DB), Group 1 (GPI) and Centene (CNC) should be on an investor's watchlist.

Sweta Killa headshot

5 Dividend Stocks With High Growth Prospects

by Sweta Killa

Cardinal Health (CAH), Toll Brothers (TOL), Iron Mountain (IRM), NetApp (NTAP) and Ralph Lauren (RL) have strong dividend growth prospects.

Davita (DVA) Shares Gain This Week: Will the Rally Continue?

by Zacks Equity Research

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

by Zacks Equity Research

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Best Growth Stocks to Buy for March 8th

by Zacks Equity Research

POWL, CAH and PAGS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 8, 2023.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.

Abbott (ABT) to Reduce Childhood Malnutrition With New Pact

by Zacks Equity Research

Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

by Zacks Equity Research

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

by Zacks Equity Research

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40

by Zacks Equity Research

ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.

Here's Why You Should Hold on to Neogen (NEOG) Stock Now

by Zacks Equity Research

Solid progress in long-term growth strategies bodes well for Neogen (NEOG).

Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPUS

Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

by Zacks Equity Research

Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

by Zacks Equity Research

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

Are Investors Undervaluing Cardinal Health (CAH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Stryker (SYK) Completes First Arthroplasty Surgery in Europe

by Zacks Equity Research

Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.